|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial显示文摘AIM To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of nonalcoholic steatohepatitis(NASH).METHODS Twelve patients with biopsy-proven NASH were randomized to sitagliptin(100 mg daily)(n=6)or placebo(n=6)for 24 wk.The primary outcome was improvement in liver fibrosis after 24 wk.Secondary outcomes included evaluation of changes in NAFLD activity score(NAS),individual components of NAS(hepatocyte ballooning,lobular inflammation,and steatosis),glycemic control and insulin resistance[including measurements of glycated hemoglobin(Hb A1C)and adipocytokines],lipid profile including free fatty acids,adipose distribution measured using magnetic resonance imaging(MRI),and thrombosis markers(platelet aggregation and plasminogen activator inhibitor 1 levels).We also sought to determine the correlation between changes in hepatic fat fraction(%)[as measured using the Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation(IDEAL)MRI technique]and changes in hepatic steatosis on liver biopsy.RESULTS Sitagliptin was not significantly better than placebo at reducing liver fibrosis score as measured on liver biopsy(mean difference between sitagliptin and placebo arms,0.40,P=0.82).There were no significant improvements evident with the use of sitagliptin vs placebo for the secondary histologic outcomes of NAS total score as well as for the individual components of NAS.Compared to baseline,those patients who received sitagliptin demonstrated improved Hb A1C(6.7%±0.4%vs 7.9%±1.0%,P=0.02),and trended towards improved adiponectin levels(4.7±3.5μg/m L vs 3.9±2.7μg/m L,P=0.06)and triglyceride levels(1.26±0.43 mmol/L vs 2.80±1.64 mmol/L,P=0.08).However,when compared with placebo,sitagliptin did not cause a statistically significant improvement in Hb A1C(mean difference,-0.7%,P=0.19)nor triglyceride levels(mean difference-1.10mmol/L,P=0.19)but did trend towards improved adiponectin levels only(mean difference,0.60μg/m L,P=0.095).No significant changes in anthropometrics,liver enzymes,other adipocytokines,lipid profile,thrombosis parameters,or adipose distribution were demonstrated.The MRI IDEAL procedure correlated well with steatosis scores obtained on liver biopsy in both groups at baseline and post-treatment,and the Spearman correlation coefficients ranged from r=0.819(baseline)to r=0.878(post-treatment),P=0.002.CONCLUSION Sitagliptin does not improve fibrosis score or NAS after 24 wk of therapy.The MRI IDEAL technique may be useful for non-invasive measurement of hepatic steatosis. | Tisha R Joy Charles A McKenzie Rommel G Tirona Kelly Summers Shannon Seney Subrata Chakrabarti Neel Malhotra Melanie D Beaton | 2017 | World Journal of Gastroenterology2017，23，1： | 18 |
| 2 | Management of non-alcoholic fatty liver disease in 2015显示文摘There is no single pharmacologic therapy that has been approved to treat nonalcoholic fatty liver disease in the general population. The backbone of therapy currently includes intensive lifestyle modification withestablished targets for diet and weight loss. The use of unsweetened, unfiltered coffee along with limiting high fructose corn syrup have emerged as beneficial dietary recommendations. The use of empiric oral hypoglycemic agents and vitamin E, however, has not been widely accepted. Developing bariatric surgical techniques are promising, but additional studies with long-term follow up are needed before it can be widely recommended. Finally, liver transplantation is an increasingly frequent consideration once complications of endstage disease have developed. The future treatment of those with nonalcoholic fatty liver disease will likely involve a personalized approach. The importance of the gut microbiome in mediating hepatocyte inflammation and intestinal permeability is emerging and may offer avenues for novel treatment. The study of anti-fibrotic agents such as pentoxifylline and FXR agonists hold promise and new pathways, such as hepatocyte cannabinoid receptor antagonists are being studied. With the incidence of obesity and the metabolic syndrome increasing throughout the developed world, the future will continue to focus on finding novel agents and new applications of existing therapies to help prevent and to mediate the progression of nonalcoholic fatty liver disease. | Neel Malhotra Melanie D Beaton | 2015 | World Journal of Hepatology2015，7，30： | 6 |
| 3 | Diagnostic tools in male infertility--the question of sperm dysfunction显示文摘精子机能障碍是不孕的最最普通的原因,还是显著的的,是那,没有一个人能服或把 vitro 加在一起到他的精子改进富饶的药。为在这个区域的进步的缺乏的一个原因是我们成熟 spermatazoon 的细胞、分子的活动方式的理解是有限的。然而,在最后几年,在我们的知识库并且在探讨新方法诊断精子机能障碍有可观的进步。我们考察这块地的当前的状态并且为进一步的开发提供卓见。我们结束那:在那里的(i) 是从用一个基本精液评价识别 / 分类人的各种各样的人口的更多的研究要增加的很少,在一个努力在保证分析以一个适当高质量的方法被执行被要求的地方;(ii ) 工艺的开发是可能的带精子功能更近测试到实现进临床的小径的现实。在做这,这些试金一定是柔韧的,便宜(或更适当地称为合算) ,易用、临床上有用;并且(iii ) 临床的必要性,例如,为注射识别高质量的精子的需要向前正在驾驶基本研究。这是一令人激动的时间是 andrologist 并且,多半多产的。 | Christopher LR Barratt Steven Mansell Catherine Beaton Steve Tardif Senga K Oxenham | 2011 | Asian Journal of Andrology2011，13，1： | 5 |
| 4 | 亚洲地区硫肥经营管理的重要思考显示文摘亚太地区对于植物S营养给农业带来的效益已广为人知.本地区一些主要国家所进行的大量田间试验清楚地表明,投入足够的硫肥给作物所带来的产出是令人满意的.在亚太绝大部分地区,普通过磷酸钙(SSP)多年来一直是当作基本的P肥使用.继续使用这种肥料将自然而然地改善和防止缺硫现象.对中国缺硫土壤的地区和缺硫程度的评估说明,有效硫含量低的土壤决不仅仅在中国南方存在,而且也广泛地分布在中国北方.已有不少报道指出,施用硫肥明显地增加了作物产量.这些作物既包括了粮食作物、蔬菜、水果,还包括了工业用作物和经济作物.对中国历来生产和消费的硫酸铵和过磷酸钙(普钙)的一项调查表明,施用普钙既是土壤的主要P,又是S的来源.近年来, 由于普钙的施用, 每年大约可提供270万吨植物S营养. 尽管普钙的生产预计会逐渐减少, 但这种肥料仍将继续成为中国农田的重要硫源.由于普钙作为一种肥料有着不可避免的缺点,在中国人们注意到了在普钙的普遍施用中存在的问题.比如,在亚太地区足P土壤或持S 力弱或淋S多或淋S(SO4)力强的土壤,普钙就不是一种理想的肥料.基于这些认识,就生产出种种新型的或改良的(缓和的)硫肥.这些肥料主要包括元素硫(S0)的添加.这就需要根据特定土壤P、S肥力状况有选择地安排生产,并激励硫肥生产技术的不断改进.本文列举了许多例子描述了此类作为植物S营养的新型和改良的S肥,阐明了它们的生产、性质和特效.在亚太地区,长期以来把元素S看作作物的有效硫源.它的优点在于其含S成分非常高,运、储、使用既经济又便当,分解缓慢肥效长;与N、P、K肥配合施用时可灵活地调节S 的浓度.本文同时将参比粗粒元素S在农艺上的无效性,介绍了元素S在氧化成SO42-过程中的细度问题. 本文简要介绍了现有的两种商品粒状硫肥(S0)的制造技术.这种肥料的优点是具有一定的分散性,粒径几微米,颗粒大小适中.文章并着重强调了这种含S颗粒肥料在平衡施肥项目中以及作为复合肥(复混肥)配料的优越性.本文同时讨论了从有效硫含量高低悬殊很大的土样中获得的平均值用来估计需硫量,往往会作出过高或过低的判断等问题. | J D Beaton A M Henderson | 2000 | 安徽农业大学学报2000，27，z1： | 5 |
| 5 | Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography显示文摘 | Robert P. Myers Aaron Pollett Richard Kirsch Gilles Pomier‐Layrargues Melanie Beaton Mark Levstik Andres Duarte‐Rojo David Wong Pam Crotty Magdy Elkashab | 2012 | Liver Int2012，，6： | 4 |
| 6 | Phase II clinical trial of phlebotomy for non‐alcoholic fatty liver disease显示文摘 | M. D. Beaton S. Chakrabarti M. Levstik M. Speechley P. Marotta P. Adams | 2013 | Aliment Pharmacol Ther2013，，7： | 3 |
| 7 | Cross-culture adaptation of health-related quality of life measures: literature review and proposed guidelines 显示文摘 | Guillemin F Bombardier C Beaton D | 1993 | J Clin Epidemiol1993，46，12： | 1 |
| 8 | Guidelines for the process of cross-cultural adaptation of self-report measures 显示文摘 | Beaton DE Bombardier C Guillemin F | 2000 | Spine ( Phila Pa 1976 )2000，25，： | 1 |
| 9 | Sulphate formation and extraction from red soil treated with micronized elemental sulphur fertilizer and incubated in closed and open systems显示文摘 | Hu Z Y Beaton J D Cao Z H | 2002 | Communication on Soil Science and Plant Analysis2002，33，1112： | 1 |
| 10 | Guidelines for the process of cross - cultural adaptation of self - report measures 显示文摘 | Beaton DE Bombardier C Guillemin F | 2000 | Spine2000，25，24： | 1 |
| 11 | Gmde-lines for the process of cross - cultural adaptation of self -report measures显示文摘 | Beaton D E Bcnnkardier C Guillemin F | 2000 | Spine2000，25，24： | 1 |
| 12 | The development uf a scale to measure childbirth expectations显示文摘 | Gupton A Beaton J Sluan J | 1990 | The Canadian of Nursing Research1990，23，2： | 1 |
| 13 | Improved response, better outcomes:theOntarioTelemedicine Network and the SouthwesternOntario Stroke Strategy use videoconferencing todeliver optimal care显示文摘 | Beaton JM | 2007 | Healthc Inform2007，24，： | 1 |
| 14 | Guidelines for the process of cross-cultural adaptation of self-report measures 显示文摘 | Beaton DE Bombardier C Guillemin F | 2000 | Spine (Phila Pa 1976)2000，25，24： | 1 |
| 15 | Guidelines for the process of cross-cultural adaptation of self-report measures显示文摘 | Beaton DE Bombardier C Guillemin F Ferraz MB | 2000 | Spine (Phila Pa 1976)2000，25，24： | 1 |
| 16 | Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter Study显示文摘 | Dan Turner Anthony R. Otley David Mack Jeffrey Hyams J. de Bruijne Krista Uusoue Thomas D. Walters Mary Zachos Petar Mamula Dorcas E. Beaton A. Hillary Steinhart Anne M. Griffiths | 2007 | Gastroenterology2007，，2： | 1 |
| 17 | Industrial Ultrafiltration Design and Application of Diafihration process显示文摘 | Beaton N C Klinkowski P R | 1983 | Separ Proc Technol1983，4，2： | 1 |
| 18 | Comparative effective- ness of patient education methods for type 2 diabetes :a randomized con- trolled trial显示文摘 | Sperl - Hillen J Beaton S Feruandes O | 2011 | Arch Intern Med2011，171，22： | 1 |
| 19 | Validity of obser-based aggregate scoring systems as desriptors of elbow pain, function, and disability 显示文摘 | Turchin DC Beaton DE Richards RR | 1998 | J Bone Joint-Surg (Am)1998，80，2： | 1 |
| 20 | Work of breathing in anesthetized infants increases when a breathing system filter is used显示文摘 | Bell G T Martin K M Beaton S | 2006 | Paediatr Anaesth2006，16，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员